STRUCTURE BASED DRUG DESIGNING, SCORING, AND SYNTHESIS OF SOME SUBSTITUTED SULPHONYLUREAS/GUANIDINE -BASED DERIVATIVES AS HYPOGLYCEMIC AGENTS
Objective: The present work deals with the designing, scoring, synthesis and, characterization of 1-(4-(2-(4-Substitutedphenylamino)-2-oxoethyl)phenylsulfonyl)-3-(4-substitutedbenzoyl)urea (5A-5B),1-(4-(2-(4-substitutedphenylamino)-2-oxoethyl)phenylsulfonyl)-3-(4-substituted-benzoyl)guanidine(5C-5E) and, 1-(4-Substitutedbenzoyl)-3-(4-(2-oxo-2-(piperazin-1-yl)ethyl)phenylsulfonyl)urea (5F-5H) based derivatives as hypoglycemic agents.
Methods: Docking calculations were performed to predict the binding affinity between the AKR1C1 complexes and sulphonylureas compounds using the Glide docking program. Docking studies on LigPrep treated ligands were carried out to predict the binding pocket of protein 4YVP using the docking program. The QikProp program was used to predict the ADME/T properties of the analogues. All these newly synthesized compounds were screened for their in vivo hypoglycemic activity by most relevant animal models like alloxan-induced diabetic rats by measuring blood plasma concentration compared with reference drug glibenclamide.
Results: Novel compounds 1-(4-(2-(4-Substitutedphenylamino)-2-oxoethyl)phenylsulfonyl)-3-(4-substitutedbenzoyl)urea (5A-5B), 1-(4-(2-(4-substitutedphenylamino)-2-oxoethyl)phenylsulfonyl)-3-(4-substitutedbenzoyl) guanidine (5C-5E), and 1-(4-Substitutedbenzoyl)-3-(4-(2-oxo-2-(piperazin-1-yl)ethyl)phenylsulfonyl)urea (5F-5H) were synthesised and characterized using spectral and analytical data. The results of molecular docking and in vivo hypoglycemic activity, all compounds have shown considerable activity with respect to glibenclimide, but compounds 5D (52.49Â±7.73) and 5E(48.18Â±4.22)are equipotent with respect to activity as compared to standard glibenclamide(55.97Â±3.19).
Conclusion: Compounds 5D and 5E have exhibited good hypoglycemic activity,hence both the derivatives will consider as a lead molecule and further some modification in their structures to get a more potent anti-diabetic agent.
2. Diptimayee D, Prasanjit KD, Ratan JL. To evaluate the hypoglycemic effect of the fruit pulp extract of spondias pinnata Linn. Kurz on experimental Model of diabetes mellitus. Asian J Pharm Clin Res 2016;9:113-6.
3. Sridhar G. Diabetes in India: a snapshot of a panorama. Curr Sci 2000;83:791.
4. Kamaeswara R, Giri R, Kesavulu M, Apparao C. Effect of oral administration of bark extracts of Pterocarpussantalinus L. on blood glucose level in experimental animals. J Ethnopharmacol 2001;74:69-74.
5. Olefsky J, Garvey W, Henry R, Brillon D, Matthael S, Freidenberg G. Cellular mechanisms of insulin resistance in non-insulin-dependent (type II) diabetes. Am J Med 1998;5A:86.
6. Dhanaji V, Umesh R, Neha R, Arvind K, Ramrao A. Synthesis and antihyperglycemic evaluation of new 2,4-thiazolidine dione shaving biodynamic aryl sulfonylurea moieties. Bioorg Med Chem Lett 2012;22:436â€“9.
7. Xiongyu W, Yiqian W, Bianca P, Milad B, Mathias A. Aryl benzylimidazole having selective angiotensin II AT2 receptor agonists activity. J Med Chem 2006;49:7160â€“8.
8. Satyanand T, Sachin K, Amit K, Mohit S. Synthesis of analogues of sulphonylureas as antidiabetic drugs and their structure-activity studies. Int J Pharm Res 2010;1:1-16.
9. Ean Yves W, Jean-Michel D, Angela C, Andrea S. Carbonic anhydrase inhibitors having anti-diabetic activity. J Med Chem 2005;48:2121-4.
10. Hermenegilda M, Rafael V, Rolffy O, Daniel D, Gabriel NV. N-(6-substituted-1,3-benzothiazol-2-yl)benzenesulfonamides having anti-diabetic activity. Bioorg Med Chem Lett 2008;18:2871â€“7.
11. Nouraddin H, Soodeh S, Mohamad E, Mohammad H, Mehdi K, Saeed Fallah B, et al. Synthesis and antidiabetic evaluation of benzenesulfonamide derivatives. Ira J Pharma Res 2013; 12:325-30.
12. Santosh N, Elgire R, Nikhil S, Devanand B. Synthesis, the hypolipidemic and hypoglycemic activity of some novel 2-(4-(2-substituted aminothiazole-4-yl)phenoxy)-2-methyl propanoic acid derivatives. Bioorg Med Chem Lett 2011;21:682â€“5.
13. Ishan IP, Dhrubo JS, Bhavesh P, Samir KS. Serendipity of fluorine in discovery and development of antidiabetic agents: a bottleneck systemic review. World J Pharm Sci 2013;1:168-75.
14. Panchal I, Panigrahi B, Modh K, Patel CN. Design, synthesis and biological evaluation of some substituted sulphonyl urea/guanidine derivatives as hypoglycemic agents. Der Pharm Chem 2011;3:383-91.
15. Hui-bin Z, Ya-an Z, Guan-zhong W, Jin-pei Z, Wen-long H, Xiao-wen Hu. Synthesis and biological evaluation of sulfonylurea and thiourea derivatives substituted with benzenesulfonamide groups as potential hypoglycemic agents. Bioorg Med Chem Lett 2009;19:1740â€“4.
16. Hong Woo L, Bok Young K, Joong Bok Ahn, Sung Kwon K, Jung Hwa L, Jae Soo S, et al. Molecular design, synthesis and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione. Eur J Med Chem 2005;40:862â€“74.
17. Hassan M, Khalid A, Abdullah M. Synthesis and biological evaluation of new 3,5-di(trifluoromethyl)-1,2,4-triazolesul-fonylurea and thiourea derivatives as antidiabetic and antimicrobial agents. J Fluo Chem 2011;132:870â€“7.
18. Abbas A, Mohsen K, Khadijeh K, Majid F, Babak NN. Synthesis and investigating hypoglycemic and hypolipidemic activities of some glibenclamide analogues in rats. Mini-Revi Med Chem 2014;14:208-13.
19. Schneider S, Ueberberg S, Korobeynikov A, Schechinger W, Schwanstecher C, Schwanstecher, et al. Synthesis and evaluation of a glibenclamide glucose-conjugate: a potential new lead compound for substituted Glibenclamide derivatives as islet imaging agents. Regulatory Peptides 2007;139:122-7.
20. Alok ST, Ravitas D, Arvind KJ, P Sudhir K. Synthesis and oral hypoglycemic effect of novel thiazine containing trisubstituted benzenesulfonylurea derivatives. Sau Pharma J 2015;23:475â€“82.
21. Zhao Y, Zheng X, Zhang H, Zhai J. In vitro inhibition of AKR1Cs by sulphonylureas and the structural basis. Chem Biol Interact 2015;240:310-5.
22. Sarath SK, Anjali T. In silico design and molecular docking studies of some 1, 2-benzisoxazole derivatives for their analgesic and anti-inflammatory activity. Int J Curr Pharm Res 2017;9:133-6.
23. Patel S, Shah U, Patel M, Upadhyay J. Molecular docking and in silico ADMET study reveals flavonoids as a potential inhibitor of aromatase. Lett Drug Design Discovery 2017;14:1-10.
24. Glideusermanual.isp.ncifcrf.gov/files/isp/uploads/2010/07/gli55_user_manual.html. [Last assessed on 20 Jan 2016]
25. Kerns EH, Li Di. Drug-like properties: concepts, structure design and methods: from ADME to Toxicity Optimization, Elsevier, San Diego, California; 2008.
26. Penny W. The comparison of friedel-crafts alkylation and acylation as a means to synthesize alkyl xylenes. Plymouth Student Scientist 2016;9:252-96.
27. Dhrubo JS, Ishan IP, Ashish DP. ScifinderÂ® as a latest tool in innovative research within a new dimension for integrating scientific chemical databases. Eur J Pharma Med Res 2016;3:1-19.
28. Stanely M, N Kamalakkannan, Venugopal P. Antidiabetic and antihyperlipidaemic effect of alcoholic syzigium cumini seeds in alloxan induced diabetic albino rats. J Ethnopharmacol 2004:91:209â€“13.
29. Prakash S, Maji D, Samanta S, Sinha R. Design, synthesis and antidiabetic, cardiomyopathy studies of cinnamic acid-amino acid hybrid analogs. Med Chem 2014;4:345-50.
30. Prabu M, Kumuthakalavalli R. Antidiabetic potential of the oyster mushroom pleurotus florida (mont.) singer. Int J Curr Pharm Res 2017;9:51-4.